Your browser doesn't support javascript.
loading
CYP4V2 fatty acid omega hydroxylase, a druggable target for the treatment of metabolic associated fatty liver disease (MAFLD).
Osborne, Nicholas; Leahy, Charles; Lee, Yoon-Kwang; Rote, Paula; Song, Byoung-Joon; Hardwick, James P.
Affiliation
  • Osborne N; Northeast Ohio Medical Universities, Department of Integrative Medical Sciences, Rootstown, OH 44272, United States.
  • Leahy C; Northeast Ohio Medical Universities, Department of Integrative Medical Sciences, Rootstown, OH 44272, United States.
  • Lee YK; Northeast Ohio Medical Universities, Department of Integrative Medical Sciences, Rootstown, OH 44272, United States.
  • Rote P; Internal Medicine University of Minnesota Health Care System, Minneapolis, MN 55455, United States.
  • Song BJ; Section of Molecular Pharmacology and Toxicology, Laboratory of Membrane Biochemistry and Biophysics, 5625 Fishers Lane Room 3N-01, MSC 9410, Bethesda, MD 20892, United States.
  • Hardwick JP; Northeast Ohio Medical Universities, Department of Integrative Medical Sciences, Rootstown, OH 44272, United States.
Biochem Pharmacol ; 195: 114841, 2022 01.
Article in En | MEDLINE | ID: mdl-34798124
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cytochrome P-450 CYP4A / Fatty Acids / Fatty Liver / Cytochrome P450 Family 4 / Liver Type of study: Risk_factors_studies Limits: Animals / Humans Language: En Journal: Biochem Pharmacol Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cytochrome P-450 CYP4A / Fatty Acids / Fatty Liver / Cytochrome P450 Family 4 / Liver Type of study: Risk_factors_studies Limits: Animals / Humans Language: En Journal: Biochem Pharmacol Year: 2022 Document type: Article Affiliation country: Country of publication: